Praziquantel, sold under the brand name Biltricide, is one of the most widely used antiparasitic drugs in the world, and one of the most studied through decades of public health treatment campaigns. This article sets out, plainly and without exaggeration, what the actual evidence shows about its use in children, during pregnancy and breastfeeding, and in older adults — where the data are strong, where they remain limited, and how prescribers weigh those gaps against the real cost of leaving a parasitic infection untreated.
What praziquantel is and how it works
Praziquantel is an isoquinoline-pyrazine compound developed jointly by Bayer AG and E. Merck in the 1970s and approved by the FDA in 1982. It sits on the World Health Organization's List of Essential Medicines and is the mainstay treatment for schistosomiasis (a fluke infection acquired through contact with contaminated fresh water), liver and lung flukes such as Clonorchis and Paragonimus, and tapeworm infections including taeniasis. It is also used, under specialist supervision, for neurocysticercosis.
Its mechanism is a fine piece of biological specificity. Praziquantel disrupts calcium regulation across the worm's outer tegument, producing sustained muscular contraction that paralyses the parasite, while also damaging the tegument surface enough to expose the worm to attack by the host's own immune system. Human cells are far less sensitive to this calcium effect, which is why a single-day course can clear an infection without broadly disturbing normal physiology. It is a reasonable thing to notice, in a compound born of careful chemistry, that the created order includes exploitable differences between parasite and host — the kind of asymmetry that makes selective, non-destructive treatment possible at all.
Praziquantel in children
Dosing in children is calculated on the same milligram-per-kilogram basis as in adults: typically 40 mg/kg given in divided doses over one day for intestinal or urinary schistosomiasis, up to 60 mg/kg divided over three doses for Schistosoma japonicum, and a single 5–10 mg/kg dose for common tapeworm infections. Current US prescribing information covers patients one year of age and older, and safety data from that age upward are extensive.
Much of the confidence in pediatric use comes not from a single pivotal trial but from decades of mass drug administration campaigns coordinated by the WHO across sub-Saharan Africa, Asia, and Latin America, in which hundreds of millions of school-age children (roughly ages 5 to 14) have received annual or biennial praziquantel doses with an accumulated safety record that is about as large as any antiparasitic has ever been given in the field.
Preschool children were historically left out of these programs, largely because tablets were bitter, hard to swallow whole, and had not been formally studied in very young children. Field studies conducted in East Africa over the past fifteen years — testing crushed tablets mixed with food in children as young as one — found the drug reasonably well tolerated, which supported the WHO's 2022 decision to extend treatment recommendations down into the preschool age group. More recently, a purpose-built orodispersible pediatric formulation, developed through the Pediatric Praziquantel Consortium, received a positive scientific opinion from European regulators in 2024 for children roughly three months to six years old — a formulation still working its way through national approvals rather than one broadly available everywhere yet. In children, as in adults, the most common effects are transient headache, abdominal discomfort, dizziness, and occasional hives, usually resolving within a day.
Pregnancy: weighing an infection against a theoretical risk
This is the area readers most often want a straight answer on, and the honest answer requires two parts held together. First, there is no completed randomized controlled trial of praziquantel in pregnant women — for the same ethical reasons that pregnant women are rarely enrolled in drug trials generally. Animal reproduction studies have not shown teratogenic effects at clinically relevant doses, but animal data are not a substitute for human evidence.
Second, human evidence does exist, just not from randomized trials. Observational studies conducted in schistosomiasis-endemic regions of Africa, including work coordinated through the WHO's Special Programme for Research and Training in Tropical Diseases in the early 2000s, followed women who were treated during pregnancy — some deliberately, some inadvertently before pregnancy was recognized — and did not find a consistent increase in miscarriage, stillbirth, or birth defects compared with untreated women. On the strength of this accumulated experience, the WHO revised its position so that pregnancy is no longer treated as an automatic bar to treatment; national programs now weigh the infection itself, which is associated with maternal anemia and can affect fetal growth, against the drug's now better-characterized safety margin. The US manufacturer label remains more cautious in its wording, advising use in pregnancy only when clearly needed — a standard regulatory posture for any drug lacking trial-level pregnancy data, not a claim that harm has been demonstrated.
Framed plainly: treating a pregnant woman's schistosomiasis is also an act of care toward the child she is carrying, since untreated infection carries its own downstream risks to fetal growth through maternal anemia. This is exactly the kind of decision that belongs to a woman and her own physician, weighing her specific infection, trimester, and circumstances rather than a blanket rule in either direction.
Breastfeeding mothers
Praziquantel and its metabolites do pass into breast milk, but at low concentrations. Older manufacturer guidance suggested withholding breastfeeding on the day of dosing and for 72 hours afterward, largely out of precaution rather than documented harm. More recent expert reviews, and the WHO's own guidance for treatment campaigns — which explicitly includes lactating women among those eligible for treatment — reflect a shift toward viewing the infant's actual drug exposure through milk as low relative to the doses used directly and safely in infants themselves. A nursing mother who needs treatment should still discuss timing with her physician or pediatrician, particularly if her infant is premature or very young, but current evidence does not support routine interruption of breastfeeding as a blanket rule.
Older adults and patients with other health conditions
There is no dedicated large geriatric trial of praziquantel, and none is really needed to justify standard use: age itself is not a specific concern, and dosing is not adjusted purely for being older. What matters more in older adults is what tends to accompany age — reduced liver reserve, chronic illness, and polypharmacy.
Praziquantel undergoes extensive first-pass metabolism in the liver. Patients with significant hepatic impairment, including the liver changes that can accompany longstanding untreated schistosomiasis or fluke infection, clear the drug more slowly and reach higher blood levels, which is a reasonable point for dose caution in that group. Kidney function matters much less, since very little of the active drug leaves the body unchanged through the kidneys.
Drug interactions deserve real attention in an older population likely to be on other medications. Enzyme-inducing drugs such as rifampin, and anticonvulsants like phenytoin or carbamazepine, can sharply lower praziquantel blood levels — pharmacokinetic studies have documented reductions large enough to risk treatment failure — while enzyme-inhibiting drugs can push levels higher. Anyone older, or on long-term seizure or tuberculosis medication, should have their full medication list reviewed by their physician or pharmacist before starting praziquantel, which is simply good stewardship of a treatment that works well when used correctly.
Safety profile across all groups
Across ages, the adverse effect profile is consistent: headache, dizziness, drowsiness, abdominal pain, nausea, and occasionally hives, generally mild and short-lived. One clear exception applies regardless of age: praziquantel must not be used for ocular cysticercosis, since killing larvae lodged in the eye can trigger an inflammatory reaction that permanently damages vision. In neurocysticercosis affecting the brain, the same die-off reaction can provoke swelling and seizures, which is why treatment is given alongside corticosteroids and anticonvulsants and under specialist supervision — a reminder that even a well-tolerated drug requires a physician's judgment about the specific infection being treated, not just the patient's age.
Key takeaway: Praziquantel has one of the largest real-world safety records of any antiparasitic drug, supporting its use from early childhood through old age and, when clinically warranted, in pregnancy and breastfeeding — but every decision should still be made individually with your own physician, weighing the specific infection against the person in front of them.